PhD
Professor, Division of Clinical Immunology & Allergy, Department of Medicine, McMaster University
Canada Research Chair, Allergy & Immune Tolerance
Honorary Professorial Research Fellow, Faculty of Medicine, Imperial College (UK)
Dr. Larché is an accomplished researcher with interests in translational medicine; the development of peptide-based vaccines for chronic immunological diseases including asthma, allergy, autoimmunity and transplantation-related diseases; the immunological mechanisms of asthma; human in vivo experimental models of T lymphocyte activation and mast cell-independent asthma; and experimental in vivo modeling of asthma, scleroderma, systemic lupus erythematosus (SLE) and GVHD.
Dr. Larché is an Associate Editor of Respiratory Research and a member of the editorial board of Clinical Experimental Immunology and Clinical Experimental Allergy. He has authored over 100 scientific papers and has been the recipient of several international prizes for his work including The Respiratory 2000 International Young Investigator Award, The Henning Lowenstein Research Award and the Pharmacia Allergy Research Foundation Award .
Together with Professor AB Kay, Dr. Larché founded the biotechnology company Circassia Ltd. to develop vaccines for allergic diseases.
All CIC publications featuring Dr. Larché as a co-author are listed below.
| Author(s) | Year | Title | Journal |
|---|---|---|---|
| Gauvreau GM, Boulet L-P, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M , Kipling C , Dua B , Mosesova S , Putnam W , Zheng Y, Scheerens H, McClintock D , Matthews J, O'Byrne PM | 2014 |
OX40L blockade on allergen-induced airway responses in subjects with mild asthma |
Clinical Experimental Allergy |